Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRVI 
Maravai Lifesciences Holdings Inc (MRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: MRVI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4
1 Year Target Price $4
| 5 | Strong Buy |
| 1 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.08% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 13 | Beta 0.33 | 52 Weeks Range 1.67 - 8.54 | Updated Date 10/14/2025 |
52 Weeks Range 1.67 - 8.54 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.57% | Operating Margin (TTM) -75.3% |
Management Effectiveness
Return on Assets (TTM) -5.89% | Return on Equity (TTM) -54.84% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 523374985 | Price to Sales(TTM) 5.31 |
Enterprise Value 523374985 | Price to Sales(TTM) 5.31 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 144677773 | Shares Floating 92644412 |
Shares Outstanding 144677773 | Shares Floating 92644412 | ||
Percent Insiders 10.16 | Percent Institutions 90.04 |
Upturn AI SWOT
Maravai Lifesciences Holdings Inc
Company Overview
History and Background
Maravai Lifesciences was founded in 2014. It focuses on providing critical products to enable the development of drug therapies, novel vaccines, and diagnostics.
Core Business Areas
- Nucleic Acid Production: Manufactures nucleic acids for research, therapeutic, and diagnostic applications. Key products include mRNA, DNA, and RNA oligonucleotides.
- Biologics Safety Testing: Provides testing and analysis services to ensure the safety and purity of biopharmaceutical products. Detects impurities such as host cell proteins and endotoxins.
- Protein Detection: Offers products for protein analysis and detection, including antibodies and immunoassay kits.
Leadership and Structure
The leadership team includes Trey Martin (CEO). The company has a typical corporate structure with functional departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- CleanCap mRNA capping technology: CleanCap is a proprietary mRNA capping technology used in mRNA-based therapeutics and vaccines. The competitors are TriLink BioTechnologies (now part of Danaher), Aldevron (now part of Danaher), and Jena Bioscience. Maravai captures a significant portion of this market. Reported revenue related to COVID mRNA vaccines have significantly diminished but may increase for other applications in the future.
- Antibodies: Offers a wide range of antibodies for research and diagnostic purposes. Competitors include Thermo Fisher Scientific (TMO), Bio-Rad Laboratories (BIO), and Cell Signaling Technology. The antibodies are primarily used in basic research and drug discovery by academic and commercial clients.
- Cygnus Technologies Products: Provides host cell protein (HCP) kits and reagents for biologics safety testing. Competitors include Thermo Fisher Scientific (TMO) and Charles River Laboratories (CRL). The revenue from this product is not publicly disaggregated.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing strong growth, driven by advancements in genomics, personalized medicine, and the increasing prevalence of chronic diseases. The growth is impacted by global economy, funding environment, innovation, and regulatory factors.
Positioning
Maravai Lifesciences is positioned as a key supplier of critical materials and services for biopharmaceutical development. Its competitive advantages include proprietary technologies and a focus on high-quality products.
Total Addressable Market (TAM)
The TAM for Maravai's products is estimated to be in the billions of dollars, encompassing nucleic acid production, biologics safety testing, and protein detection. They are well positioned to capture portions of the TAM with focus in mRNA therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary Technologies
- Strong Customer Relationships
- High-Quality Products
- Experienced Management Team
Weaknesses
- Reliance on a Few Key Products
- Dependence on Biopharmaceutical Industry
- Exposure to Regulatory Changes
- High Customer Concentration
Opportunities
- Expansion into New Markets
- Development of New Products
- Acquisitions of Complementary Businesses
- Increased Demand for Biopharmaceutical Products
Threats
- Competition from Larger Companies
- Price Pressure
- Technological Disruption
- Economic Downturn
Competitors and Market Share
Key Competitors
- TMO
- DHR
- CRL
Competitive Landscape
Maravai Lifesciences competes with both large and small companies in its various product segments. Its competitive advantages include proprietary technologies and a focus on high-quality products. Its disadvantages include its smaller size and limited product portfolio compared to larger competitors.
Major Acquisitions
TriLink BioTechnologies
- Year: 2021
- Acquisition Price (USD millions): 1625
- Strategic Rationale: The acquisition of TriLink BioTechnologies expands Maravai's capabilities in nucleic acid production and enhances its product offerings for mRNA-based therapeutics and vaccines. Note: this was Danaher's acquisition
Alphazyme LLC
- Year: 2021
- Acquisition Price (USD millions): 72
- Strategic Rationale: The acquisition added new capabilities to support mRNA synthesis and supports downstream manufacturing processes.
Growth Trajectory and Initiatives
Historical Growth: Maravai Lifesciences experienced rapid growth during the COVID-19 pandemic, driven by demand for its mRNA capping technology. The growth rate has since slowed.
Future Projections: Future growth is projected to be moderate, driven by demand for biopharmaceutical products and expansion into new markets. Analyst estimates are variable, reflecting uncertainty in the biopharmaceutical industry.
Recent Initiatives: Recent initiatives include developing new products, expanding manufacturing capacity, and pursuing strategic acquisitions.
Summary
Maravai Lifesciences is a key supplier in the biopharmaceutical industry with proprietary technologies, but it faces competition from larger companies and is dependent on the biotech industry. The rapid growth experienced during the COVID-19 pandemic has slowed, and future growth depends on successful expansion into new markets and product development. While its balance sheet is strong, financial performance has declined due to reduced demand for COVID-related products. Maravai must look out for technological disruption and economic downturns that could impact its business.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10K, 10Q), Investor Presentations, Press Releases, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maravai Lifesciences Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-20 | CEO & Director Mr. Bernd Brust | ||
Sector Healthcare | Industry Biotechnology | Full time employees 560 | Website https://www.maravai.com |
Full time employees 560 | Website https://www.maravai.com | ||
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.